title: Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometrium of <or=7 mm on day of egg retrieval.
abstract: OBJECTIVE
  The objective of this study was to examine the use of gonadotrophin-releasing hormone agonist (GnRH-a) for luteal phase in a group of patients with thin endometrium (<or=7 mm) after IVF treatment.
  
  
  METHODS
  One-hundred-and-twenty women were eligible for this study. Patients were randomly allocated into two groups: group A (n = 60) received triptorelin 0.1 mg on the day of ovum pickup (OPU), on the day of embryo transfer (ET) and three days thereafter, and group B (n = 60) received placebo. The primary outcomes were implantation and pregnancy rates.
  
  
  RESULTS
  Although there was no significant difference in the number of good quality embryos transferred in both groups, the implantation and pregnancy rate were significantly higher in the GnRH-a - treated group compared with placebo controls. Furthermore, Estradiol (E(2)), progesterone (P) levels and endometrial thickness were significantly more elevated in patients who received GnRH-a for luteal phase support.
  
  
  CONCLUSIONS
  The administration of GnRH-a at the time of OPU significantly improves the implantation and pregnancy rates in patients with thin endometrium (<or=7 mm).
authors.affiliation: Infertility & IVF Center, Prince Rashed Hospital, Irbid, Jordan. hqublan@yahoo.com
authors.forename: H
authors.initials: H
authors.lastname: Qublan
authors.forename: H
authors.initials: H
authors.lastname: Qublah
authors.forename: Z
authors.initials: Z
authors.lastname: Amarin
authors.forename: M
authors.initials: M
authors.lastname: Al-Qudah
authors.forename: M
authors.initials: M
authors.lastname: Al-Quda
authors.forename: F
authors.initials: F
authors.lastname: Diab
authors.forename: M
authors.initials: M
authors.lastname: Nawasreh
authors.forename: S
authors.initials: S
authors.lastname: Malkawi
authors.forename: M
authors.initials: M
authors.lastname: Balawneh
mesh_terms: D000328:Adult; D010064:Embryo Implantation; D004717:Endometrium / Q000473:pathology*; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D006801:Humans; D007247:Infertility, Female / Q000473:pathology / Q000628:therapy; D008183:Luteal Phase; D009865:Oocytes; D010919:Placebos; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies; D020858:Tissue and Organ Harvesting; D017329:Triptorelin Pamoate / Q000008:administration & dosage*
chemical_list: D010919:Placebos; D017329:Triptorelin Pamoate; D011374:Progesterone; D004958:Estradiol